Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment.(D-FOG)

Cancer Clinical Trial

— D-FOG  

Official title:

Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment. Feasibility and Acceptability Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03261128
• Other study ID #: 2017-A02188-45
• Status: Completed
• Start date: November 21, 2017
• Est. completion date: December 5, 2018

Study information

• Verified date: January 2019
• Source: Poitiers University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Many cancers are diagnosed after 75 years. Treatment in chemotherapy begins without evidence of geriatric risk factors. A new tool for screening for geriatric fragilities is used, a self-administered questionnaire carried out by the patient before each chemotherapy cure. The objective is to secure the quality of patient care and to detect the appearance and / or aggravation of geriatric fragilities.

Description:

Evaluation of the feasibility of a new geriatric fragility screening tool (D-FOG) in patients aged ≥ 75 years during oncological treatment:

• Number of D-FOGs filled in: comparison with the number of patients included in the study and the number of visits of each patient.

• Regularity of the D-FOG self-questionnaire by the patient: comparison with the number of visits of the patient for a chemotherapy cure (HDJ or HDS).

• Number of criteria entered by D-FOG: comparison with the total number of criteria to be filled in

• Criterion analysis of D-FOG

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 5, 2018
• Est. primary completion date: September 11, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 75 years and over

• Carriers of diagnosed cancer (excluding hematology)

• Whatever the location, uniqueness or multiple, duration of development and treatment status (adjuvant, neoadjuvant, locally advanced or metastatic)

• Seen in nursing consultant

• Beginning an oncological treatment

• Supported for oncology day hospital (HDJ) or weekly (HDS) chemotherapy

• Patient not opposed to participate in the study

Exclusion Criteria:

• Patients under 75 years of age

• Having not had an IDE ad consultation

• During oncological treatment

• Receiving Oral Therapy or hormone therapy alone

• Treated by radiotherapy alone or surgery alone

• Not attending a day or week oncology hospital

• Refusal to participate in research

Related Conditions & MeSH terms

• 75 Years Old and More
• Cancer
• Chemotherapy

Intervention

Other:
• Self-questionnaire
Filling of a self-questionnaire before each chemotherapy cure

Locations

Country	Name	City	State
France	CHU	Poitiers

Sponsors (1)

Lead Sponsor	Collaborator
Poitiers University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the feasibility of a new geriatric fragility screening tool (D-FOG) in patients aged = 75 years during oncological treatment.	Feasibility of D-FOG for patients : number of D-FOGs filled in, regularity of the D-FOG self-questionnaire by the patient, number of criteria entered by D-FOG, criterion analysis of D-FOG	3 months